Pacer Advisors Inc. Has $8.29 Million Stock Holdings in Progyny, Inc. $PGNY

Pacer Advisors Inc. reduced its holdings in Progyny, Inc. (NASDAQ:PGNY) by 28.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 385,079 shares of the company’s stock after selling 153,120 shares during the quarter. Pacer Advisors Inc. owned approximately 0.45% of Progyny worth $8,287,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. California State Teachers Retirement System increased its holdings in Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares during the period. Leibman Financial Services Inc. grew its position in shares of Progyny by 1.1% in the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after buying an additional 513 shares during the last quarter. Teza Capital Management LLC increased its stake in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares during the period. Oxford Asset Management LLP increased its stake in shares of Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares during the period. Finally, M&G PLC raised its position in shares of Progyny by 2.6% during the second quarter. M&G PLC now owns 30,542 shares of the company’s stock worth $672,000 after acquiring an additional 764 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on PGNY shares. Barclays started coverage on shares of Progyny in a research report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Monday, December 22nd. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. KeyCorp raised shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target on the stock in a research report on Tuesday, November 11th. Finally, Canaccord Genuity Group lifted their price objective on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and an average target price of $27.50.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the sale, the chief financial officer owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Peter Anevski bought 79,500 shares of the stock in a transaction dated Thursday, November 13th. The shares were purchased at an average cost of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the transaction, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This trade represents a 13.23% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders sold 22,046 shares of company stock worth $561,691. Corporate insiders own 9.40% of the company’s stock.

Progyny Stock Up 1.1%

Shares of NASDAQ PGNY opened at $25.80 on Monday. The firm has a market cap of $2.22 billion, a PE ratio of 40.95, a P/E/G ratio of 2.03 and a beta of 0.96. The company’s fifty day simple moving average is $23.63 and its 200 day simple moving average is $22.71. Progyny, Inc. has a 12-month low of $15.71 and a 12-month high of $27.76.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.06. The firm had revenue of $313.35 million for the quarter, compared to analyst estimates of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, equities analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.